Cargando…
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
The COVID-19 pandemic has had global healthcare impacts, including high mortality from SARS-CoV-2 infection in cancer patients; individuals with multiple myeloma (MM) are especially susceptible to poor outcomes. However, even for MM patients who avoided severe infection, the ramifications of the pan...
Autores principales: | Carmichael, Jonathan, Seymour, Frances, McIlroy, Graham, Tayabali, Sarrah, Amerikanou, Rosie, Feyler, Sylvia, Popat, Rakesh, Pratt, Guy, Parrish, Christopher, Ashcroft, A. John, Jackson, Graham H., Cook, Gordon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015143/ https://www.ncbi.nlm.nih.gov/pubmed/36922489 http://dx.doi.org/10.1038/s41408-023-00795-w |
Ejemplares similares
-
A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction
por: Chandler, Thea, et al.
Publicado: (2023) -
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
por: Cook, Gordon, et al.
Publicado: (2020) -
Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent
por: Feyler, Sylvia, et al.
Publicado: (2012) -
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010) -
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)